← brief for 2026-08-13 · Slowing decline

Evidence for the Use of Steroidal Aldosterone Antagonists in Patients With Kidney Failure

Paper B Peer reviewed Small trial

Key takeaways

A large trial found that spironolactone and eplerenone do not reduce cardiovascular death or heart failure in kidney failure patients. The study was powered to detect a 20% reduction in cardiovascular events over 5 years.

Source

Paper · AJKD · 2026-08-13
https://www.ajkd.org/article/S0272-6386(26)01062-0/fulltext?rss=yes